COMPARATIVE EFFICACY AND SAFETY PROFILE OF 5 MG ROSUVASTATIN VERSUS 10 MG ROSUVASTATIN IN PATIENTS WITH ISCHEMIC HEART DISEASE
Article Sidebar
Main Article Content
Abstract
Objectives: To compare the efficacy and clinical profile of 5 mg rosuvastatin versus 10 mg rosuvastatin in improving
the management of patients with IHD.
Material and Methods: This study was jointly conducted by Department of Pharmacology, Khyber Medical College,
and Cardiology Department of Khyber Teaching Hospital from January 2011 to August 2011. The patients presenting
to coronary care unit and cardiology OPD were randomized into a two groups; Group A and Group B each
comprising 50 patients. Group A recieved 5 mg of rosuvastatin and Group B received 10 mg of resovuastatin for three
months. National cholesterol Education programme adult treat panel III (NCEP ATP III) guideline for LDL-C was
chosen as the primary objective while assessing the safety profile and toxicity was considered the secondary end
point. A rise in HDL-C was also anticipated.
Results: Thirty-four (68%) patients in group A and 41 (82%) patients in group B were male. All the patients were
resident of Peshawar. Their mean ages were 51.4 ± 7.6 and 49.35 ± 5.65 years respectively in group A and B. The
LDL-C dropped to NCEP ATP III value of < 100 mg% in 3 (26%) patients in group A compared to 4 (88%) in group B
P < 0.0004. LDL-C levels after the 3 month treatment showed a mean reduction of 66.2 ± 3.8 and 84.1 ± 4.3 in group
A and B respectively implying 39.02% and 48.38 % reduction with a P value < 0.0001. The reduction to total
cholesterol (TLC) was 31.69% (mean 83.2 ± 7.5) and 41.28% (mean 107.0 ± 3.3) in the respective groups with a P
value of < 0.0001. The significant value for triglycerids was a P < 0.04 for group B while the HDL-C improvement was
0.0006 in group B (receiving 10 mg rosuvastatin). The reported increased in the incidence of myalgia and muscle
weakness was statistically insignificant P < 0.06.
Conclusion: Rosuvastatin; clinically proven antilipidemic agent for the management of IHD has a better efficacy with
almost identical adverse effects in 10 mg doses as compared with 5 mg doses and this satisfies the NCEPATP III
guidelines.
Article Details
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.